Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Reproduction

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1645590

This article is part of the Research TopicNew Advances in Embryo Development and Embryo-endometrial InterfaceView all articles

Women's thalassemia status and embryo carrier status do not affect pregnancy outcomes after euploid transfers

Provisionally accepted
Li  FanLi FanZhetao  LiZhetao LiWugao  LiWugao LiLiuyan  WeiLiuyan WeiNi  TangNi TangLiuying  NongLiuying NongJingjing  LiJingjing LiWenjie  HuangWenjie Huang*
  • Liuzhou Maternal and Child Health Hospital, Liuzhou, China

The final, formatted version of the article will be published soon.

Background: While preimplantation genetic testing for monogenic disorders (PGT-M) is widely applied to prevent transmission of severe thalassemia, limited evidence exists regarding the impact of thalassemia carrier status or embryo genotype on pregnancy outcomes in patients undergoing preimplantation genetic testing for aneuploidy (PGT-A). Methods: This retrospective cohort study included 981 women who underwent their first autologous IVF cycle with single euploid embryo transfer at a tertiary reproductive center between January 2016 and December 2023. Among them, 512 were classified as having thalassemia (including heterozygous carriers and non–transfusion-dependent cases), and 460 were non-thalassemia controls. All participants underwent PGT-A, with a subset also receiving concurrent PGT-M. Clinical outcomes—including clinical pregnancy, live birth, and miscarriage rates—were compared between groups using Poisson regression models, adjusting for age, BMI, and endometrial thickness. Additional subgroup analyses stratified patients by age (<35 vs. ≥35 years) and embryo genotype (thalassemia carrier vs. non-carrier). Results: Thalassemia patients were significantly younger and had lower BMI and thicker endometrium compared to non-thalassemia patients. However, no statistically significant differences were found in clinical pregnancy (67.8% vs. 63.0%, aRR = 1.05, 95% CI: 0.94–1.16), live birth (61.9% vs. 53.3%, aRR = 1.08, 95% CI: 0.96–1.23), or miscarriage rates (5.9% vs. 9.8%, aRR = 0.82, 95% CI: 0.49–1.40) between the groups after adjustment. Furthermore, within the broadly defined thalassemia group, no significant differences were observed between embryos with and without pathogenic thalassemia variants. Interaction analyses showed no synergistic effects between thalassemia status and clinical variables. Conclusion: Thalassemia status and embryo genotype do not appear to adversely affect pregnancy outcomes following euploid embryo transfer. These findings support the transfer of heterozygous carrier embryos and suggest that individualized reproductive counseling and embryo selection strategies can be safely applied in couples at genetic risk of thalassemia undergoing IVF with PGT.

Keywords: Thalassemia, PGT-A, euploid embryo transfer, live birth rate, Reproductive outcomes

Received: 12 Jun 2025; Accepted: 09 Oct 2025.

Copyright: © 2025 Fan, Li, Li, Wei, Tang, Nong, Li and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Wenjie Huang, a17377552242@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.